Deininger MWN, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia Blood 2000 96: 3343–3356 CASPubMed Google Scholar
Daley G, ven Etten R, Baltimore D . Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome Science 1990 247: 824–830 ArticleCASPubMed Google Scholar
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 1996 2: 561–566 ArticleCASPubMed Google Scholar
Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA . Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia Anticancer Drugs 1994 5: 213–222 ArticleCASPubMed Google Scholar
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD . STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells Blood 2000 95: 2118–2125 CASPubMed Google Scholar
Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037 ArticleCASPubMed Google Scholar
Druker BJ, Sawyer CL, Kantarjian H, Resta D, Reese SF, Ford J, Capdeville R, Talpaz M . Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001 344: 1038–1042 ArticleCASPubMed Google Scholar
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieseer D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B . Hematologic and cytogenetic responses to Imatinib mesylate in chronic myelogenous leukemia N Engl J Med 2002 346: 645–652 ArticleCASPubMed Google Scholar
Talpaz M, Silver R, Druker B, Goldman J, Gambacorti-Passerini C, Guilhot F, Schiffer C, Fischer T, Deininger MWN, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fermandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 2002 99: 1928–1937 ArticleCASPubMed Google Scholar
Savage DG, Antman KH . Imatinib mesylate–a new oral targeted therapy N Engl J Med 2002 346: 683–693 ArticleCASPubMed Google Scholar
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293: 876–879 ArticleCASPubMed Google Scholar
Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon F-X . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a Article Google Scholar
Hochhaus A, Kreil S, Corbin A, Rosee PL, Lahaye T, Berger U, Cross NCP, Linkesch W, Druker BJ, Hehlmann R . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a Article Google Scholar
Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP . Ph+ acute lymphblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 2002 99: 1860–1862 ArticlePubMed Google Scholar
Von Bubnoff N, Schneller F, Peschel C, Duyster J . Bcr-Abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: a prospective study Lancet 2002 359: 487–491 ArticleCASPubMed Google Scholar
Branford S, Zbigniew R, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP . High frequency of point mutations clustered within the adnosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 2002 99: 3472–3475 ArticleCASPubMed Google Scholar
Sirulink A, Silver RT, Najfeld V . Marked ploid and BCR-ABL gene amplification in vivo in a patient treated with STI571 Leukemia 2001 15: 1795–1797 ArticleCASPubMed Google Scholar
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C . Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia Proc Natl Acad Sci USA 1999 96: 12804–12809 ArticleCASPubMedPubMed Central Google Scholar
Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HDH, Moore CW . Biochemical and cellular effects of c-src selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors Biochem Pharm 2000 60: 885–898 ArticleCASPubMed Google Scholar
Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM . 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure–activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity J Med Chem 1998 41: 3276–3292 ArticleCASPubMed Google Scholar
Vang T, Tasken K, Skalhegg BS, Hansson V, Levy FO . Kinetic properties of the C-terminal Src kinase, p50csk Biochim Biophys Acta 1998 1384: 285–293 ArticleCASPubMed Google Scholar
Villalba M, Wente SR, Russell DS, Ahn JC, Reichelderfer CF, Rosen OM . Another version of the human insulin receptor kinase domain: expression, purification, and characterization Proc Natl Acad Sci USA 1989 86: 7848–7852 ArticleCASPubMedPubMed Central Google Scholar
Gu H, Griffin JD, Neel BG . Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells J Biol Chem 1997 272: 16421–16430 ArticleCASPubMed Google Scholar
Dorsey JF, Jove R, Kraker AJ, Wu J . The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells Cancer Res 2000 60: 3127–3131 CASPubMed Google Scholar
Cunnick JM, Dorsey JF, Munoz-Antonia T, Mei L, Wu J . Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor J Biol Chem 2000 275: 13842–13848 ArticleCASPubMed Google Scholar
Carrol M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland G, Druker BJ . CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins Blood 1997 90: 4947–4951 Google Scholar